Roche plans expansion of Indianapolis site to manufacture CGMs

Roche Diagnostics is planning a $550 million expansion at its Indianapolis, Indiana, headquarters to begin manufacturing its Accu-Chek Smartguide continuous glucose monitors (CGMs) within the next three years. The investment will support both current and future CGM production and is expected to generate 650 new jobs. The company will renovate part of its existing facility and may add new buildings depending on demand.

The Indianapolis site serves as Roche’s North American hub for research, manufacturing, and distribution, including its Accu-Chek test strip production. The Smartguide CGM, which received CE Mark approval in mid-2024, is designed for 14-day wear and uses predictive technology to estimate glucose trends and detect nighttime low blood sugar risks. However, unlike some competing devices, it still requires users to perform finger-stick calibrations.

Though not yet cleared in the U.S., Roche said it is progressing through the necessary steps to bring the product to the American market as part of a broader $50 billion U.S. investment plan.

18-05-2025